Activation of JAK/STAT signaling can also be achieved by JAK3, JAK1, or STAT5B mutations, reported in approximately 7%, 4%, and 1% of T-ALL cases, respectively. The gene discussed is STAT5B; the disease is acute lymphoblastic leukemia.